CompletedPhase 2NCT01404949
Combined Tretinoin and Arsenic Trioxide for Patients With Newly Diagnosed Acute Promyelocytic Leukemia Followed by Risk-Adapted Postremission Therapy
Studying Acute promyelocytic leukemia
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Principal Investigator
- Jae Park, MDMemorial Sloan Kettering Cancer Center
- Intervention
- Tretinoin and Arsenic Trioxide(drug)
- Enrollment
- 17 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2011 – 2021
Study locations (12)
- University of Southern California, Los Angeles, California, United States
- Northwestern University, Evanston, Illinois, United States
- National Heart, Lung, and Blood Institute (NIH), Bethesda, Maryland, United States
- Memorial Sloan Kettering at Basking Ridge, Basking Ridge, New Jersey, United States
- Memorial Sloan Kettering Monmouth, Middletown, New Jersey, United States
- Memorial Sloan Kettering Cancer Center @ Suffolk, Commack, New York, United States
- Memorial Sloan Kettering Westchester, Harrison, New York, United States
- Memorial Sloan Kettering Cancer Center, New York, New York, United States
- New York Presbyterian Hospital-Weill Medical College of Cornell University, New York, New York, United States
- Memorial Sloan Kettering at Mercy Medical Center, Rockville Centre, New York, United States
- Cleveland Clinic, Cleveland, Ohio, United States
- Princess Margaret Hospital/Ontario Cancer Institute, Toronto, Ontario, Canada
Collaborators
Northwestern University · New York Presbyterian Hospital · University of Southern California · Princess Margaret Hospital, Canada · National Heart, Lung, and Blood Institute (NHLBI)
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT01404949 on ClinicalTrials.govOther trials for Acute promyelocytic leukemia
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE2NCT07563179Bugitinib Combined With Venetoclax and Cytarabine in Relapsed/Refractory Acute Myeloid LeukemiaShenzhen University General Hospital
- RECRUITINGPHASE3NCT07504458Pivotal Open-label Phase 3 Clinical Study of QTX-2101 in Adult Patients With Acute Promyelocytic LeukemiaQuetzal Therapeutics
- RECRUITINGPHASE3NCT07223814Bleximenib in Combination With Standard Induction and Consolidation Therapy Followed by Maintenance for Treatment of Patients With Acute Myeloid Leukemia (AML)Stichting Hemato-Oncologie voor Volwassenen Nederland
- ACTIVE NOT RECRUITINGNANCT07187505Venetoclax Combined With ATRA and ATO in Hyperleukocytic Acute Promyelocytic LeukemiaAnhui Medical University
- RECRUITINGPHASE3NCT07503730Early Use of Realgar-Indigo Naturalis Formula (RIF) Combined With All-trans Retinoic Acid (ATRA) for Treating Acute Promyelocytic Leukemia (APL).First Affiliated Hospital Xi'an Jiaotong University
- ENROLLING BY INVITATIONNANCT06697327Daunorubicin + Cytarabine + Venetoclax in de Novo AMLAnhui Medical University
- RECRUITINGPHASE1NCT06313437Revumenib in Combination With 7+3 + Midostaurin in AMLRichard Stone, MD
- RECRUITINGPHASE3NCT06578247Quizartinib or Placebo Plus Chemotherapy in Newly Diagnosed Patients With FLT3-ITD Negative AMLDaiichi Sankyo